These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24731533)

  • 1. The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients.
    Vaidya A; Borgonovi E; Taylor RS; Sahel JA; Rizzo S; Stanga PE; Kukreja A; Walter P
    BMC Ophthalmol; 2014 Apr; 14():49. PubMed ID: 24731533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal Prosthesis System for Advanced Retinitis Pigmentosa: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2016; 16(14):1-63. PubMed ID: 27468325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal Prosthesis System for Advanced Retinitis Pigmentosa: A Health Technology Assessment Update.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(13):1-62. PubMed ID: 29201260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, effectiveness, and cost-effectiveness of Argus II in patients with retinitis pigmentosa: a systematic review.
    Ostad-Ahmadi Z; Daemi A; Modabberi MR; Mostafaie A
    Int J Ophthalmol; 2021; 14(2):310-316. PubMed ID: 33614463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind.
    Ho AC; Humayun MS; Dorn JD; da Cruz L; Dagnelie G; Handa J; Barale PO; Sahel JA; Stanga PE; Hafezi F; Safran AB; Salzmann J; Santos A; Birch D; Spencer R; Cideciyan AV; de Juan E; Duncan JL; Eliott D; Fawzi A; Olmos de Koo LC; Brown GC; Haller JA; Regillo CD; Del Priore LV; Arditi A; Geruschat DR; Greenberg RJ;
    Ophthalmology; 2015 Aug; 122(8):1547-54. PubMed ID: 26162233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial.
    da Cruz L; Dorn JD; Humayun MS; Dagnelie G; Handa J; Barale PO; Sahel JA; Stanga PE; Hafezi F; Safran AB; Salzmann J; Santos A; Birch D; Spencer R; Cideciyan AV; de Juan E; Duncan JL; Eliott D; Fawzi A; Olmos de Koo LC; Ho AC; Brown G; Haller J; Regillo C; Del Priore LV; Arditi A; Greenberg RJ;
    Ophthalmology; 2016 Oct; 123(10):2248-54. PubMed ID: 27453256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.
    Kaplan RI; De Moraes CG; Cioffi GA; Al-Aswad LA; Blumberg DM
    JAMA Ophthalmol; 2015 May; 133(5):560-7. PubMed ID: 25741886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved performance and safety from Argus II retinal prosthesis post-approval study in France.
    Delyfer MN; Gaucher D; Mohand-Saïd S; Barale PO; Rezaigua-Studer F; Ayello-Scheer S; Dollfus H; Dorn JD; Korobelnik JF; Sahel JA
    Acta Ophthalmol; 2021 Nov; 99(7):e1212-e1221. PubMed ID: 33354943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study.
    White J; Knight L; da Cruz L; Stanga PE; Patrick H; Powell H; Berry L; Withers K; Carolan-Rees G; Jackson TL
    JMIR Res Protoc; 2021 Jan; 10(1):e17436. PubMed ID: 33470946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical coherence tomography imaging in the management of the Argus II retinal prosthesis system.
    Parmeggiani F; De Nadai K; Piovan A; Binotto A; Zamengo S; Chizzolini M
    Eur J Ophthalmol; 2017 Jan; 27(1):e16-e21. PubMed ID: 28009400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive Visual Phenomena Following Implantation of the Argus II Retinal Prosthesis.
    Sadaka A; Iqbal C; Nazari H; Berry S; Wykoff CC; Humayun MS; Lee AG
    Ophthalmic Surg Lasers Imaging Retina; 2017 Dec; 48(12):1022-1025. PubMed ID: 29253307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argus II retinal prosthesis for retinitis pigmentosa in the Middle East: The 2015 Pan-American Association of Ophthalmology Gradle Lecture.
    Arevalo JF; Al Rashaed S; Alhamad TA; Al Kahtani E; Al-Dhibi HA;
    Int J Retina Vitreous; 2021 Oct; 7(1):65. PubMed ID: 34706764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
    Salcedo J; Bulovic J; Young CM
    Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.